The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Unoprostone     (E)-7-[(1R,2R,3R,5S)-3,5- dihydroxy-2-(3...

Synonyms: SureCN2469324, LS-172447, AKOS015899623, AC1O637O, A804496, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Unoprostone


High impact information on Unoprostone


Chemical compound and disease context of Unoprostone


Biological context of Unoprostone


Anatomical context of Unoprostone


Associations of Unoprostone with other chemical compounds


Gene context of Unoprostone

  • And finally, deesterified unoprostone carboxylate was found to be transported by OATP1A2, OATP2B1 and OATP4A1 with approximate K(m)-values of 93, 91 and 132 microm, respectively [15].
  • The endothelin-induced increase (679 +/- 102 nM), however, was almost completely (P < 0.01) blocked by unoprostone (178 +/- 40 nM) [6].
  • In addition, unoprostone interacts with the maxi-K channel [6].
  • Lastly, unoprostone has vasorelaxant properties, evidenced by increased choroidal blood flow and inhibition of vasoconstrictors such as endothelin-1 [21].
  • CONCLUSIONS: The unoprostone metabolite M1 protects retinal neuro-glial progenitor R28 cells from apoptosis induced by serum deprivation via the PI3K and PKG pathways [12].

Analytical, diagnostic and therapeutic context of Unoprostone


  1. Safety of unoprostone isopropyl as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension. de Arruda Mello, P.A., Yannoulis, N.C., Haque, R.M. Drug safety : an international journal of medical toxicology and drug experience. (2002) [Pubmed]
  2. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%. McCarey, B.E., Kapik, B.M., Kane, F.E. Ophthalmology (2004) [Pubmed]
  3. Effects of topical unoprostone and latanoprost on acute and recurrent herpetic keratitis in the rabbit. Kaufman, H.E., Varnell, E.D., Toshida, H., Kanai, A., Thompson, H.W., Bazan, N.G. Am. J. Ophthalmol. (2001) [Pubmed]
  4. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Sharif, N.A., Kelly, C.R., Crider, J.Y. Invest. Ophthalmol. Vis. Sci. (2003) [Pubmed]
  5. Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Yu, D.Y., Su, E.N., Cringle, S.J., Schoch, C., Percicot, C.P., Lambrou, G.N. Invest. Ophthalmol. Vis. Sci. (2001) [Pubmed]
  6. Mechanisms of action of unoprostone on trabecular meshwork contractility. Thieme, H., Stumpff, F., Ottlecz, A., Percicot, C.L., Lambrou, G.N., Wiederholt, M. Invest. Ophthalmol. Vis. Sci. (2001) [Pubmed]
  7. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Susanna, R., Giampani, J., Borges, A.S., Vessani, R.M., Jordao, M.L. Ophthalmology (2001) [Pubmed]
  8. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Nordmann, J.P., Mertz, B., Yannoulis, N.C., Schwenninger, C., Kapik, B., Shams, N. Am. J. Ophthalmol. (2002) [Pubmed]
  9. Cystoid macular edema associated with ocular hypotensive lipids. Wand, M., Gaudio, A.R. Am. J. Ophthalmol. (2002) [Pubmed]
  10. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Day, D.G., Schacknow, P.N., Wand, M., Sharpe, E.D., Stewart, J.A., Leech, J., Stewart, W.C. Am. J. Ophthalmol. (2003) [Pubmed]
  11. Partial antagonism of endothelin 1-induced vasoconstriction in the human choroid by topical unoprostone isopropyl. Polska, E., Doelemeyer, A., Luksch, A., Ehrlich, P., Kaehler, N., Percicot, C.L., Lambrou, G.N., Schmetterer, L. Arch. Ophthalmol. (2002) [Pubmed]
  12. Unoprostone isopropyl rescues retinal progenitor cells from apoptosis in vitro. Mukuno, H., Nakamura, M., Kanamori, A., Nagai, A., Negi, A., Seigel, G. Curr. Eye Res. (2004) [Pubmed]
  13. Effect of topical unoprostone on circulation of human optic nerve head and retina. Tamaki, Y., Araie, M., Tomita, K., Nagahara, M., Sandoh, S., Tomidokoro, A. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2001) [Pubmed]
  14. Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2)induction, affinity to prostaglandin transporter, and intraocular metabolism. Kashiwagi, K., Kanai, N., Tsuchida, T., Suzuki, M., Iizuka, Y., Tanaka, Y., Tsukahara, S. Exp. Eye Res. (2002) [Pubmed]
  15. Localization of organic anion transporting polypeptides in the rat and human ciliary body epithelium. Gao, B., Huber, R.D., Wenzel, A., Vavricka, S.R., Ismair, M.G., Remé, C., Meier, P.J. Exp. Eye Res. (2005) [Pubmed]
  16. Vasodilatory mechanism of unoprostone isopropyl on isolated rabbit ciliary artery. Yoshitomi, T., Yamaji, K., Ishikawa, H., Ohnishi, Y. Curr. Eye Res. (2004) [Pubmed]
  17. Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. Kelly, C.R., Williams, G.W., Sharif, N.A. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  18. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arcieri, E.S., Santana, A., Rocha, F.N., Guapo, G.L., Costa, V.P. Arch. Ophthalmol. (2005) [Pubmed]
  19. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure. Stewart, W.C., Stewart, J.A., Kapik, B.M. Journal of glaucoma. (1998) [Pubmed]
  20. Iris-color change developed after topical isopropyl unoprostone treatment. Yamamoto, T., Kitazawa, Y. Journal of glaucoma. (1997) [Pubmed]
  21. Neuroprotective properties of a synthetic docosanoid, unoprostone isopropyl: clinical benefits in the treatment of glaucoma. Melamed, S. Drugs under experimental and clinical research. (2002) [Pubmed]
  22. In vivo measurement of iridial circulation using laser speckle phenomenon. Tomidokoro, A., Araie, M., Tamaki, Y., Tomita, K. Invest. Ophthalmol. Vis. Sci. (1998) [Pubmed]
  23. Unoprostone isopropyl ester darkens iris color in pigmented rabbits with sympathetic denervation. Zhan, G.L., Toris, C.B., Meza, J.L., Camras, C.B. Journal of glaucoma. (2003) [Pubmed]
  24. Metabolites of isopropyl unoprostone as potential ophthalmic solutions to reduce intraocular pressure in pigmented rabbits. Kashiwagi, K., Iizuka, Y., Tsukahara, S. Jpn. J. Pharmacol. (1999) [Pubmed]
WikiGenes - Universities